[특허]Compositions and methods for treating cancer by modulating HER-2 and EGF receptors

Compositions and methods for treating cancer by modulating HER-2 and EGF receptors 원문보기

IPC분류정보
국가/구분	United States(US) Patent 등록
국제특허분류(IPC7판)	A61K-038/17 A61K-039/395 A61K-051/08 A61K-051/02
출원번호	UP-0344470 (2001-08-14)
등록번호	US-7608269 (2009-11-10)
국제출원번호	PCT/US01/025502 (2001-08-14)
§371/§102 date	20030905 (20030905)
국제공개번호	WO02/014470 (2002-02-21)
발명자 / 주소	Clinton, Gail M.
출원인 / 주소	Oregon Health and Science University
대리인 / 주소	Davison, Barry L.
인용정보	피인용 횟수 : 0 인용 특허 : 43

초록 ▼

An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor. Herstatin blocked the activated Akt-mediated EGF survival signal, as well as transforming growth factor alpha (TGFα)-mediated EGF receptor activation, survival signal and proliferation signal. Purified recombinant herstatin specifically inhibited human carcinoma cells that over-express HER-2, and was effectively absorbed into the blood of intraperitoneally injected mice, where it was not proteolytically degraded and was present for between one and three hours.

대표청구항 ▼

The invention claimed is: 1. A method for targeting a therapeutic agent to solid tumor tissue, wherein the solid tumor tissue is characterized by expression of EGF receptor, comprising attaching the therapeutic agent to an isolated polypeptide having from about 50 to 79 contiguous amino acid residues of SEQ ID NO: 1, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 108M-1; and administering the attached therapeutic agent to a subject in need thereof determined to have a tumor characterized by expression of EGF receptor. 2. The method for targeting a therapeutic agent to solid tumor tissue of claim 1, wherein the isolated polypeptide is from about 69 to 79 contiguous amino acid Residues of SEQ ID NO:1. 3. A method for targeting a therapeutic agent to solid tumor tissue, wherein the solid tumor tissue is characterized by expression of EGF receptor, comprising attaching the therapeutic agent to an isolated polypeptide having from about 50 to 79 contiguous amino acid residues of a sequence selected from the group consisting of SEQ ID NOS: 11, 15 and 17-26, wherein the polypeptide binds to the extracellular domain of EGF receptor with an affinity binding constant of at least 10 8M31 1; and administering the attached therapeutic agent to a subject in need thereof determined to have a tumor characterized by expression of EGF receptor. 4. The method of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:11, 15 and 17-26. 5. The method of claim 3, wherein the isolated polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOS:11, 15 and 17-26. 6. The method of claim 3, wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NO:11. 7. The method of claim 3, wherein the isolated polypeptide consists of the amino acid sequence of SEQ ID NO:11. 8. The method of claim 3, wherein the solid tumor that expresses EGF receptor is at least one selected from the group consisting of squamous cell carcinoma, lung carcinoma, colon carcinoma, and glial cell tumors.

이 특허에 인용된 특허 (43)

Plowman Gregory D. ; Culouscou Jean-Michel ; Shoyab Mohammed ; Siegall Clay B. ; Hellstrom Ingegerd ; Hellstrom Karl E., Antibodies to HER4, human receptor tyrosine kinase.
상세보기
Arakawa Tsutomu ; Kita Yoshiko, Antibody-induced apoptosis.
상세보기
Ring David B., Antigen-binding sites of antibody molecules specific for cancer antigens.
상세보기
Marks Jeffrey R. ; Vaughn James P. ; Inglehart James D., Antisense oligonucleotides against ERBB-2.
상세보기
Cockerill George Stuart,GBX ; Carter Malcolm Clive,GBX ; Guntrip Stephen Barry,GBX ; Smith Kathryn Jane,GBX, Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
상세보기
Lupu Ruth ; Lippman Marc E., Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2 receptor.
상세보기
Greene Mark I. ; Qian Xiaolan, Compositions and methods of treating tumors.
상세보기
Mark I. Greene ; Donald M. O'Rourke ; Ramachandran Murali ; Byeong-Woo Park, Compositions and methods of treating tumors.
상세보기
Greene Mark I. ; Zhang Xin, Compounds that bind to p185 and methods of using the same.
상세보기
Carney Walter P. (North Andover MA) McKenzie Sara J. (Lynn MA), Detection and quantification of neu related proteins in the biological fluids of humans.
상세보기
Carney, Walter P.; McKenzie, Sara J.; Weinberg, Robert A., Detection of neu p185 in cell lysates.
상세보기
Kenneth A. Thomas, Jr. ; Richard L. Kendall ; Corey K. Goldman ; William R. Huckle ; Andrew J. Bett, Gene therapy for inhibition of angiogenesis.
상세보기
Wels Winfried S.,DEX ; Schmidt Mathias,DEX ; Vakalopoulou Evangelia,DEX ; Schneider Douglas W, Growth factor receptor antibodies.
상세보기
Joni Kristin Doherty ; Gail M. Clinton, HER-2 binding antagonists.
상세보기
Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel, HER2 extracellular domain.
상세보기
Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel,DEX, HER2 extracellular domain.
상세보기
Kendall Richard L. ; Mao Xianzhi ; Thomas Kenneth A. ; Tebben Andrew, Human receptor tyrosine kinase, KDR.
상세보기
Richard L. Kendall ; Xianzhi Mao ; Kenneth A. Thomas ; Andrew Tebben, Human receptor tyrosine kinase, KDR.
상세보기
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
상세보기
David Gary S. (La Jolla CA) Greene Howard E. (Carlsbad CA), Immunometric assays using monoclonal antibodies.
상세보기
Hudziak Robert M. ; Ullrich Axel ; Fendly Brian M., In vivo tumor detection assay.
상세보기
Adhip P. N. Majumdar, Isolation and characterization of a rat epidermal growth factor related protein.
상세보기
Greene Mark I. (Penn Valley PA) Dobashi Kunio (Gunma PA JPX) Davis James G. (Philadelphia PA) Hamuro Junji (Yokahama JPX), Ligand for the neu gene product.
상세보기
Lippman Marc E. (Bethesda MD) Lupu Ruth (Gaithersburg MD), Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses.
상세보기
Waterfield Michael D. (London GB2) Schlessinger J. (Rehovot CA ILX) Ullrich Axel (South San Francisco CA), Method of detecting truncated epidermal growth factor receptors.
상세보기
Bacus Sarah S. (Hinsdale IL), Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy.
상세보기
Raymond A. Koski, Methods and compositions for determining HER-2/neu expression.
상세보기
Ho Wei-Hsien ; Osheroff Phyllis L., Methods involving sensory and motor neuron derived factor (SMDF).
상세보기
Greene Mark I., Methods of treating cancerous cells with anti-receptor antibodies.
상세보기
Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
상세보기
Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
상세보기
Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
상세보기
Clinton, Gail M., N-terminally truncated HER-2/neu protein as a cancer prognostic indicator.
상세보기
Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
상세보기
King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., Protein related to but distinct from EGF receptor and antibodies reactive therewith.
상세보기
Boyd Andrew W.,AUX ; Simpson Richard,AUX ; Wicks Ian,AUX ; Ward Larry David,AUX ; Wilkinson David,AUX, Receptor-type tyrosine kinase and use thereof.
상세보기
Wels Winfried S. (Basel CHX) Hynes Nancy E. (Basel CHX) Harweth Ina-Maria (Grenzach-Wyhlen DEX) Groner Bernd (Basel CHX) Hardman Norman (Riehen CHX) Zwickl Markus (Basel CHX), Recombinant antibodies specific for a growth factor receptor.
상세보기
Terman Bruce Israel ; Carrion Miguel Eduardo, Recombinant kinase insert domain containing receptor and gene encoding same.
상세보기
Ho Wei-Hsien ; Osheroff Phyllis L., Sensory and motor neuron derived factor (SMDF).
상세보기
Ladner Robert C. (Ijamsville MD) Bird Robert E. (Rockville MD) Hardman Karl (Chevy Chase MD), Single polypeptide chain binding molecules.
상세보기
Kluender Harold Clinton Eugene ; Benz Guenter Hans Heinz Herbert,DEX ; Brittelli David Ross ; Bullock William Harrison ; Combs Kerry Jeanne ; Dixon Brian Richard ; Schneider Stephan,DEX ; Wood Jill E, Substituted 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors.
상세보기
Margolis Ben Lewis ; Schlessinger Joseph, Treatment or diagnosis of diseases or conditions associated with a BLM domain.
상세보기
King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., erbB-2 gene segments, probes, recombinant DNA and kits for detection.
상세보기

내보내기 메뉴

내보내기 구분

파일저장
인쇄
메일전송

구성항목

기본정보
상세정보

관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC

저장형식

Text(ASCII format)
Excel format
PIAS분석(.xls)

메일정보

받는사람 (필수): @
보내는사람 (선택): @
제목
내용: KISTI 검색결과 이메일 서비스

안내

총 건의 자료가 검색되었습니다.

다운받으실 자료의 인덱스를 입력하세요. (1-10,000)

검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다.

데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요)

다운로드 파일은 UTF-8 형태로 저장됩니다.
파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오.

Text(ASCII format)
Excel format

AI-Helper ※ AI-Helper는 을 사용합니다.

AI-Helper

안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

IPC	Description
A	생활필수품
A62	인명구조; 소방(사다리 E06C)
A62B	인명구조용의 기구, 장치 또는 방법(특히 의료용에 사용되는 밸브 A61M 39/00; 특히 물에서 쓰이는 인명구조 장치 또는 방법 B63C 9/00; 잠수장비 B63C 11/00; 특히 항공기에 쓰는 것, 예. 낙하산, 투출좌석 B64D; 특히 광산에서 쓰이는 구조장치 E21F 11/00)
A62B-1/08	.. 윈치 또는 풀리에 제동기구가 있는 것

연합인증

Compositions and methods for treating cancer by modulating HER-2 and EGF receptors 원문보기

초록 ▼

대표청구항 ▼

연구과제 타임라인

이 특허에 인용된 특허 (43)

관련 콘텐츠

특허 원문 보기

IPC 상위 출원인

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표IPC 관리번호, 국가코드, 자료구분, 상태, 출원번호, 출원일자, 공개번호, 공개일자, 공고번호, 공고일자, 등록번호, 등록일자, 발명명칭(한글), 발명명칭(영문), 출원인(한글), 출원인(영문), 출원인코드, 대표출원인, 출원인국적, 출원인주소, 발명자, 발명자E, 발명자코드, 발명자주소, 발명자 우편번호, 발명자국적, 대표IPC, IPC코드, 요약, 미국특허분류, 대리인주소, 대리인코드, 대리인(한글), 대리인(영문), 국제공개일자, 국제공개번호, 국제출원일자, 국제출원번호, 우선권, 우선권주장일, 우선권국가, 우선권출원번호, 원출원일자, 원출원번호, 지정국, Citing Patents, Cited Patents
저장형식	Text(ASCII format) Excel format PIAS분석(.xls)
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Compositions and methods for treating cancer by modulating HER-2 and EGF receptors 원문보기

초록 ▼

대표청구항 ▼

연구과제 타임라인

전체(0) 논문(0) 특허(0) 보고서(0)

전체(0) 논문(0) 특허(0) 보고서(0)

이 특허에 인용된 특허 (43)

관련 콘텐츠

특허 원문 보기

IPC 상위 출원인

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트